Voyager Therapeutics, Inc.
VYGR
$3.25
-$0.15-4.41%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -39.13% | -59.94% | 144.28% | -45.73% | -82.42% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -39.13% | -59.94% | 144.28% | -45.73% | -82.42% |
| Cost of Revenue | -29.65% | -21.96% | -5.71% | 18.60% | -1.95% |
| Gross Profit | 27.76% | 12.15% | 37.84% | -300.94% | -1,000.67% |
| SG&A Expenses | -28.38% | -14.30% | -8.65% | -0.92% | 3.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -29.33% | -20.17% | -6.30% | 14.45% | -0.66% |
| Operating Income | 27.94% | 12.75% | 30.99% | -122.02% | -192.42% |
| Income Before Tax | 26.72% | 9.88% | 19.13% | -208.95% | -229.81% |
| Income Tax Expenses | 33.33% | -62.16% | -98.46% | 93.02% | -37.50% |
| Earnings from Continuing Operations | 26.69% | 9.94% | 20.47% | -208.40% | -229.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.69% | 9.94% | 20.47% | -208.40% | -229.18% |
| EBIT | 27.94% | 12.75% | 30.99% | -122.02% | -192.42% |
| EBITDA | 28.34% | 12.89% | 31.93% | -134.52% | -219.41% |
| EPS Basic | 28.96% | 11.66% | 21.79% | -203.45% | -223.85% |
| Normalized Basic EPS | 29.00% | 11.63% | 30.62% | -204.12% | -330.91% |
| EPS Diluted | 28.96% | 11.66% | 21.34% | -196.44% | -216.11% |
| Normalized Diluted EPS | 29.00% | 11.63% | 30.62% | -204.12% | -330.91% |
| Average Basic Shares Outstanding | 3.21% | 1.96% | 1.66% | 1.65% | 1.64% |
| Average Diluted Shares Outstanding | 3.21% | 1.96% | 1.66% | 1.65% | 1.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |